Trump sets 2-year tariff-free window on generics before 200% rate

Generic drugmakers have a 2-year window to stockpile US inventory before tariffs surge to 200%, the administration's most aggressive onshoring push yet.

President Donald Trump granted generic drug imports a 2-year tariff exemption starting Aug. 1 before rates climb to 100% and then 200%, the administration's most aggressive push yet to force pharmaceutical production back to the United States.

"This is done to reshore generic pharmaceutical production into America, with a penalty to those companies that decide not to build plant and equipment within the stated period," Trump said in a Truth Social post Tuesday. "The objective of this policy is to protect the people of the United States."

The zero-tariff period runs from Aug. 1, 2026 through July 31, 2028. Rates then rise to 100% for one year before jumping to 200% thereafter. The policy applies exclusively to generic drugs; patented, branded and innovative drugs face no change under what Trump called a "successful" tariff framework that remains in place.

The phased escalation creates a massive incentive for companies such as Teva Pharmaceutical Industries Ltd., Sandoz, Viatris Inc. and Sun Pharmaceutical Industries Ltd. to accelerate US manufacturing investments. Generic drugs account for about 90% of all US prescriptions by volume, meaning any supply disruption or cost pass-through could ripple across the American healthcare system.

The United States imported roughly $90 billion in generic drugs annually as of 2025, according to Census Bureau data, with the majority manufactured in India and China. The previous administration's 10% global tariff under Section 122 of the Trade Act of 1974, imposed in February, had already raised questions about pharmaceutical supply chain resilience. Trump's latest move goes further by creating a hard deadline for manufacturing relocation.

Companies that fail to build US facilities within the 2-year window face a cost structure that would make imported generics prohibitively expensive. A 200% tariff on a $10 bottle of generic pills would add $20 in duties, effectively tripling the landed cost.

The Onshoring Calculus

The 2-year grace period mirrors the administration's approach to semiconductor tariffs, which offered investment incentives before imposing penalties. Pharmaceutical facilities are already being built "at a level never seen before" across the United States, Trump said, though he did not specify which companies or locations.

For generic drugmakers, the math is stark. Building a US manufacturing plant typically takes 3 to 5 years and costs $50 million to $200 million, depending on complexity. The 2-year window may force accelerated construction timelines or acquisitions of existing US facilities. The last major tariff escalation on Chinese goods in 2018 reduced bilateral trade by about $60 billion over 12 months, according to Federal Reserve research, offering a historical precedent for how quickly supply chains can shift under tariff pressure.

Winners, Losers and Healthcare Costs

US consumers and insurers could face higher generic drug costs if manufacturers pass tariff expenses through to buyers. The Kaiser Family Foundation estimated that generic drugs saved the US healthcare system $408 billion in 2024 alone. A shift to higher-cost domestic production or tariff-inflated imports could erode those savings.

Indian generic drugmakers, which supply about 40% of the US generic market by volume, face the most exposure. Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd. and Cipla Ltd. all derive significant revenue from US generics. Their stock prices could face pressure as investors price in the 2028 tariff cliff, while US-based contract manufacturers such as Catalent Inc. and Thermo Fisher Scientific Inc. could benefit from accelerated onshoring demand.

This article is for informational purposes only and does not constitute investment advice.